Skip to Main Content

Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.

If the drug succeeds, CerSci could receive an additional $887 million in payments for hitting commercial and development milestones.

advertisement

The deal is part of the company’s effort to expand on the financial success of Nuplazid, its drug for Parkinson’s-related psychosis, which generated $339 million in 2019 sales, chief executive Stephen Davis said in an interview with STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED